{"filing":{"accession_number":"0001628280-26-056999","cik":"0001836564","ticker":"VALN","company_name":"Valneva SE","form":"6-K","filing_date":"2026-08-14","report_date":"2026-12-31","primary_document":"a6-kcoverpagetemplate.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1836564/000162828026056999/a6-kcoverpagetemplate.htm"},"events":[{"id":27812,"run_id":25384,"accession_number":"0001628280-26-056999","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces that the European Medicines Agency has validated the Marketing Authorization Application (MAA) for PF-07307405, Valneva and Pfizer's Lyme disease vaccine candidate, based on favorable Phase 3 VALOR trial results (\u003e70% efficacy). This is a material regulatory milestone in the clinical development and commercialization pathway of a key pipeline asset for Valneva, but it is not a discrete event type in the taxonomy (not an earnings release, M\u0026A activity, executive change, or other named category). It represents a significant operational/strategic advancement in the vaccine development program that would affect a reasonable investor's assessment of Valneva's prospects.","company_name":"Valneva SE","ticker":"VALN","filing_date":"2026-08-14","form":"6-K","submitted_at":null,"items":[{"id":29499,"accession_number":"0001628280-26-056999","item_number":"EX-99.1","item_title":"finallymeematechnicalvalid.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces that the European Medicines Agency has validated the Marketing Authorization Application (MAA) for PF-07307405, Valneva and Pfizer's Lyme disease vaccine candidate, based on favorable Phase 3 VALOR trial results (\u003e70% efficacy). This is a material regulatory milestone in the clinical development and commercialization pathway of a key pipeline asset for Valneva, but it is not a discrete event type in the taxonomy (not an earnings release, M\u0026A activity, executive change, or other named category). It represents a significant operational/strategic advancement in the vaccine development program that would affect a reasonable investor's assessment of Valneva's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-14T15:28:39.240026+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29499,"accession_number":"0001628280-26-056999","item_number":"EX-99.1","item_title":"finallymeematechnicalvalid.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces that the European Medicines Agency has validated the Marketing Authorization Application (MAA) for PF-07307405, Valneva and Pfizer's Lyme disease vaccine candidate, based on favorable Phase 3 VALOR trial results (\u003e70% efficacy). This is a material regulatory milestone in the clinical development and commercialization pathway of a key pipeline asset for Valneva, but it is not a discrete event type in the taxonomy (not an earnings release, M\u0026A activity, executive change, or other named category). It represents a significant operational/strategic advancement in the vaccine development program that would affect a reasonable investor's assessment of Valneva's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-14T15:28:39.240026+00:00","company_name":"Valneva SE","ticker":"VALN","filing_date":"2026-08-14"}]}